Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis: A Cross-sectional Study
- PMID: 33880080
- PMCID: PMC8047686
- DOI: 10.7224/1537-2073.2020-005
Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis: A Cross-sectional Study
Abstract
Background: Vitamin D deficiency is associated with increased disease activity in multiple sclerosis (MS), but its role in progressive MS has not been elucidated. The objective was to determine the correlation between vitamin D levels and visual parameters in primary progressive MS (PPMS) and secondary progressive MS (SPMS).
Methods: Serum 25-hydroxyvitamin D (25[OH]D) and 25-hydroxyvitamin D3 (25[OH]D3) levels were obtained from the Secondary and Primary Progressive Ibudilast NeuroNEXT Trial in MS (SPRINT-MS). Visual function measurements and vitamin D associations were determined using the Pearson correlation and the generalized linear mixed model.
Results: The analysis included 258 patients (mean ± SD age of 55.6 ± 7.3 years, 52.7% female, and 52.3% PPMS). Mean vitamin D values were above sufficiency and were similar between PPMS and SPMS (P = .47 and P = .31). There was no association between 25(OH)D3 levels and any visual markers, including peripapillary retinal nerve fiber layer thickness (Spearman r = -0.08), macular volume (r = -0.03), ganglion cell-inner plexiform layer (r = -0.07), and 2.5% low-contrast visual acuity test (r = -0.10). No statistically significant associations between vitamin D levels and visual system measurements were detected in the PPMS and SPMS subgroups.
Conclusions: Vitamin D levels were not associated with optical coherence tomography findings or low-contrast letter acuity in this group of patients with progressive MS.
Keywords: Low-contrast visual acuity; Multiple sclerosis (MS); Optical coherence tomography (OCT); Progressive multiple sclerosis.
© 2021 Consortium of Multiple Sclerosis Centers.
Conflict of interest statement
Financial Disclosures: Dr Fox receives consulting fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, and Teva; serves on advisory committees for Actelion, Biogen, Immunic, and Novartis; and has received clinical trial contract and research grant funding from Biogen and Novartis. Dr Bermel is a consultant for Biogen, Genzyme, Genentech, and Novartis; receives research support from Biogen, Genentech, and Novartis; and shares rights to intellectual property underlying the Multiple Sclerosis Performance Test, currently licensed to Qr8 Health and Biogen. Dr Ontaneda has received grant support from Genzyme, Genentech, and Novartis and consulting fees from Biogen, Genzyme, and Genentech. The other authors declare no conflicts of interest.
Figures
Similar articles
-
Vitamin D and MRI measures in progressive multiple sclerosis.Mult Scler Relat Disord. 2019 Oct;35:276-282. doi: 10.1016/j.msard.2019.08.014. Epub 2019 Aug 13. Mult Scler Relat Disord. 2019. PMID: 31445221 Free PMC article.
-
Effects of Ibudilast on Retinal Atrophy in Progressive Multiple Sclerosis Subtypes: Post Hoc Analyses of the SPRINT-MS Trial.Neurology. 2023 Sep 5;101(10):e1014-e1024. doi: 10.1212/WNL.0000000000207551. Epub 2023 Jul 17. Neurology. 2023. PMID: 37460235 Free PMC article. Clinical Trial.
-
Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness.Mult Scler. 2011 Dec;17(12):1449-63. doi: 10.1177/1352458511418630. Epub 2011 Aug 24. Mult Scler. 2011. PMID: 21865411
-
A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.J Steroid Biochem Mol Biol. 2016 Nov;164:254-257. doi: 10.1016/j.jsbmb.2015.11.009. Epub 2015 Nov 17. J Steroid Biochem Mol Biol. 2016. PMID: 26598277 Review.
-
Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis.Mult Scler. 2017 Apr;23(5):734-747. doi: 10.1177/1352458517690822. Epub 2017 Feb 16. Mult Scler. 2017. PMID: 28206829 Free PMC article. Review.
Cited by
-
Retinal imaging with optical coherence tomography in multiple sclerosis: novel aspects.Wien Med Wochenschr. 2022 Nov;172(15-16):329-336. doi: 10.1007/s10354-022-00925-2. Epub 2022 Mar 28. Wien Med Wochenschr. 2022. PMID: 35347500 Free PMC article. Review.
-
Vitamin D-An Effective Antioxidant in an Animal Model of Progressive Multiple Sclerosis.Nutrients. 2023 Jul 26;15(15):3309. doi: 10.3390/nu15153309. Nutrients. 2023. PMID: 37571246 Free PMC article.
-
Vitamin D in Multiple Sclerosis-Lessons From Animal Studies.Front Neurol. 2021 Oct 20;12:757795. doi: 10.3389/fneur.2021.757795. eCollection 2021. Front Neurol. 2021. PMID: 34744990 Free PMC article. Review.
-
Comparative Profiling of TG2 and Its Effectors in Human Relapsing Remitting and Progressive Multiple Sclerosis.Biomedicines. 2022 May 26;10(6):1241. doi: 10.3390/biomedicines10061241. Biomedicines. 2022. PMID: 35740263 Free PMC article.
-
How Does Vitamin D Affect Immune Cells Crosstalk in Autoimmune Diseases?Int J Mol Sci. 2023 Feb 28;24(5):4689. doi: 10.3390/ijms24054689. Int J Mol Sci. 2023. PMID: 36902117 Free PMC article. Review.
References
-
- Soilu-Hanninen M, Aivo J, Lindstrom BM et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83:565–571. - PubMed
-
- Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832–2838. - PubMed
-
- Simpson S, Jr, Taylor B, Blizzard L et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68:193–203. - PubMed
LinkOut - more resources
Full Text Sources